Kenvue Inc. (KVUE) is valued at $27.5 billion and manages popular brands like Tylenol and Neutrogena. However, its stock has underperformed, declining 37.8% in the past 52 weeks. Shares increased by 1.5% after releasing mixed Q2 earnings, with expectations for EPS to drop 13.2% this fiscal year.

Analysts predict Kenvue’s EPS to decline 13.2% this year, with a moderate buy consensus rating. Canaccord Genuity lowered its rating to “Hold,” with a $15 price target, indicating a 5.3% upside potential. The mean price target is $19.29, a 35.5% premium from current levels, while the high target is $23.

Read more at Yahoo Finance: Do Wall Street Analysts Like Kenvue Stock?